Metformin extended-release tablets are mainly used as glucose-lowering drugs for type 2 diabetes, which is the first-line use of oral drugs in the current Chinese diabetes prevention and treatment guidelines to reduce basal and postprandial blood glucose.
Metformin hydrochloride extended-release tablets is an oral hypoglycemic drug belonging to the class of biguanides, which mainly reduces blood glucose and improves insulin sensitivity by inhibiting hepatic glucose output and increasing glucose uptake and utilization. Metformin extended-release tablets are slow-release preparations that prolong the duration of action of metformin.
Adverse effects of metformin extended-release tablets: 1. Occasionally gastrointestinal reactions such as nausea, vomiting, diarrhea, etc. 2. Weakness, fatigue, dizziness, rash. 3. Lactic acidosis, although the incidence is very low, but should be noted. 4. It can reduce intestinal absorption of vitamin B12, which reduces hemoglobin and produces megaloblastic anemia, and can also cause malabsorption.
Type 2 diabetes mellitus with ketoacidosis, hepatic and renal insufficiency (serum creatinine more than 1.5mg/dl), pulmonary insufficiency, heart failure, acute myocardial infarction, severe infections and trauma, major surgery, as well as clinical hypotension and hypoxia; previous history of lactic acidosis, and allergy to metformin extended-release tablets are prohibited.
Metformin extended-release tablets are prescription drugs and need to be used under the guidance of a doctor.